Cantor Fitzgerald Estimates SLNO FY2026 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Soleno Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn $1.22 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $123.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.19.

A number of other research firms also recently issued reports on SLNO. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Piper Sandler raised their price objective on Soleno Therapeutics from $93.00 to $145.00 and gave the company an “overweight” rating in a research note on Thursday, April 24th. Robert W. Baird boosted their target price on Soleno Therapeutics from $102.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Laidlaw upped their target price on Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, March 27th. Finally, UBS Group set a $105.00 price target on Soleno Therapeutics in a research note on Thursday, March 27th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $106.78.

Soleno Therapeutics Stock Performance

Soleno Therapeutics stock opened at $79.15 on Tuesday. The business has a fifty day moving average of $73.03 and a two-hundred day moving average of $57.61. The company has a market cap of $3.99 billion, a P/E ratio of -23.84 and a beta of -2.69. Soleno Therapeutics has a one year low of $36.93 and a one year high of $80.99.

Insider Activity at Soleno Therapeutics

In related news, CEO Bhatnagar Anish sold 699,095 shares of the business’s stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the transaction, the chief executive officer now owns 577,076 shares of the company’s stock, valued at approximately $39,021,879.12. The trade was a 54.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Patricia C. Hirano sold 3,782 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $70.11, for a total transaction of $265,156.02. Following the sale, the insider now directly owns 27,036 shares in the company, valued at $1,895,493.96. This represents a 12.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 942,672 shares of company stock valued at $64,058,781 over the last quarter. Insiders own 12.30% of the company’s stock.

Institutional Trading of Soleno Therapeutics

Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers grew its stake in Soleno Therapeutics by 5.9% in the 1st quarter. Rhumbline Advisers now owns 36,439 shares of the company’s stock worth $2,604,000 after acquiring an additional 2,044 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Soleno Therapeutics by 48.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company’s stock worth $2,909,000 after purchasing an additional 13,211 shares during the last quarter. Optimize Financial Inc purchased a new stake in shares of Soleno Therapeutics in the first quarter valued at $274,000. Woodline Partners LP increased its stake in Soleno Therapeutics by 16.0% in the first quarter. Woodline Partners LP now owns 349,664 shares of the company’s stock valued at $24,983,000 after purchasing an additional 48,102 shares during the last quarter. Finally, Fred Alger Management LLC lifted its position in Soleno Therapeutics by 172.8% during the first quarter. Fred Alger Management LLC now owns 40,394 shares of the company’s stock worth $2,886,000 after buying an additional 25,589 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.